Current Report Filing (8-k)
05 Abril 2021 - 8:42AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): March 21, 2021
GLOBAL
WHOLEHEALTH PARTNERS CORPORATION
(Exact
name of registrant as specified in its charter)
|
Nevada
|
000-56035
|
46-2316220
|
(State
or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification No.)
|
|
1402 N El
Camino Real
San
Clemente, CA
|
92672
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Registrant's
telephone number, including area code (714) 392-9752
N/A
(Former name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
¨
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Section
1 - Registrant’s Business and Operations
Item
1.01 Entry into a Material Definitive Agreement.
On
March 21, 2021, Global Wholehealth Partners Corporation (the “Company”) entered into a License Agreement
(“Agreement”) with Charles Strongo. Under the terms of the Agreement, the Company has the exclusive license to use the
following items of intellectual property:
A
Rapid, Micro-Welt or Later flow text for Parkinson’s, Dementia, or Alzheimer or ASD - The test determines the level of the
brain enzyme which has characteristics related to ASD Directly related to the hippopotamus part of the brain (Autistic Syndrome
Disorders), the lack of Top3B topoisomerases, seems to be a cause to the ASDs. The test is an enzyme test which is
semi quantitative rapid test format.
The Company agreed to issue 5,000,000 shares of common stock and
pay a 2% fee of gross sales from use of the patent. The duration of the agreement is for an initial period of five years
commencing on March 21, 2021.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
GLOBAL
WHOLEHEALTH PARTNERS CORPORATION
(Registrant)
|
|
Date:
April 5, 2021
|
By:
/s/ Charles Strongo
Charles Strongo
Chief Executive Officer
|
Global Wholehealth Partn... (CE) (USOTC:GWHP)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Global Wholehealth Partn... (CE) (USOTC:GWHP)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
